Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Clovis gets global license to Pfizer's PARP inhibitor PF01367338

Executive Summary

Pfizer Inc. has licensed Clovis Oncology Inc. (developing therapeutics and diagnostics for cancer) worldwide rights to develop and commercialize oral and IV formulations of its Phase I/II potent poly (ADP-ribose) polymerase (PARP) inhibitor PF01367338 for solid tumors.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register